A new study reveals that pharmaceutical companies have been using patenting processes to unfairly maintain high insulin costs, adding to the financial burden faced by patients and insurers. The study highlights the role of the FDA's Orange Book and the U.S. Patent and Trademark Office in governing patent ownership and market competition.
The financial burden of high insulin costs that patients and insurers face is often blamed on the Food and Drug Administration’s ( FDA ) regulatory framework, but a new study suggests pharmaceutical companies have also been using patenting processes to unfairly maintain high costs.
In the FDA’s master list of approved medications, devices, and other therapeutics, a document known as the Orange Book, patent ownership of each item governs which companies are allowed to manufacture and sell which therapies. The FDA deals with drug approval, but patents are granted by another agency entirely, the U.S. Patent and Trademark Office (USPTO). Though there are rules governing which developments by pharmaceutical companies merit inclusion in the FDA’s Orange Book, experts have long said that the book remains full of improper patents that unfairly hamper market competitio
Insulin Pharmaceutical Companies Patenting Processes FDA Orange Book USPTO Market Competition
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
UK Home Secretary's Comparison of Pro-Palestinian Demonstrations and Orange Order Marches Sparks ControversyLifelong anti-war and civil rights campaigner Eamonn McCann accuses Suella Braverman of 'stirring up trouble' ahead of pro-Palestine marches
Lire la suite »
FDA Approves Zepbound, the Most Potent Weight Loss Drug YetZepbound, made by Eli Lilly, is the newest FDA-approved drug for weight loss. (It was previously a diabetes treatment known as Mounjaro.)
Lire la suite »
Greggs reveals Christmas menu including return of popular bake and chocolate orange muffinGREGGS has unveiled its highly anticipated festive menu and the exact date it lands in shops. The bakery giant has exclusively revealed its Christmas offering to The Sun, including an all-new bake …
Lire la suite »
FDA approves Voquezna for erosive esophagitis, GERDThe U.S. Food and Drug Administration has approved Phathom Pharmaceuticals' Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal reflux disease (GERD).
Lire la suite »
FDA investigating hospitalizations linked to counterfeit OzempicThe U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of the wildly popular weight-loss drugs known as semaglutides.
Lire la suite »